01—Abstract
Summary
Summary of the 8-K filed April 26, 2024. Cited figures are marked; the original filing is the authoritative source.
This 8-K, filed April 26, 2024 by BeiGene, Ltd. (now BeOne Medicines, ticker ONC), is a supplemental disclosure rather than an earnings release.
It furnishes Exhibit 99.1, which restates selected 2023 figures under U.S. GAAP that BeiGene was required to publish under PRC rules alongside its STAR Market annual report. The exhibit covers gross margin by region, R&D spending by product, and production and inventory volumes. The filing is not subject to Section 18 liability and does not include a full earnings release or guidance.
The figures show strong 2023 top-line growth. Total revenue rose about 74% to $2.46 billiona from $1.42 billion, driven mainly by ex-China revenue, which more than doubled to $1.36 billion. China revenue grew about 31% to $1.10 billion.
Blended gross margin, calculated from the disclosed revenue and cost of goods sold, expanded to roughly 84.5% from about 79.8%. The mix shift toward high-margin ex-China sales (98% gross margin) is the main driver, while China gross margin improved modestly to 68.0%. R&D spending increased about 8% to $1.78 billionb.
Internal R&D grew about 12%c, while external R&D was nearly flat, with collaboration spending down about 40%. Within the pipeline, zanubrutinib spending rose about 25% and the Bcl-2 program (BGB-11417, now sonrotoclax) more than doubled. Ociperlimab spending fell about 27%.
The disclosure is backward-looking, so investors should treat it as historical context. Its main value is in confirming the revenue and margin trajectory and reconciling PRC and U.S. reporting.
02—Key points
Key Highlights
- Total 2023 revenue of $2.46 billion, up about 74% from $1.42 billion in 2022 (U.S. GAAP, per Exhibit 99.1).
- Ex-China revenue more than doubled to $1.36 billion (+136% YoY), while China revenue grew about 31% to $1.10 billion.
- Implied blended gross margin rose to roughly 84.5% from about 79.8%, reflected in ex-China gross margin of 98.0% and China gross margin of 68.0%.
- Total R&D expense was $1.78 billion, up about 8% YoY, with internal R&D up about 12% and external R&D up about 2%.
- Bcl-2 program (BGB-11417) R&D spending more than doubled to $52.5 million; zanubrutinib R&D rose about 25% to $158.1 million.
- Collaboration-related R&D fell about 40% to $100.1 million, and ociperlimab R&D fell about 27% to $77.7 million.
- Key product inventory at year-end 2023 was 2.67 million vials, against 3.88 million vials sold and 5.00 million vials produced or purchased during the year.
03—Questions
Frequently Asked Questions
Does this 8-K contain new earnings results or guidance?
No. The filing furnishes supplemental financial information from BeiGene's STAR Market annual report. It covers 2023 figures previously reported under U.S. GAAP and does not include a full earnings release, quarterly results, or forward-looking guidance. The information is furnished, not filed, so it is not subject to Section 18 liability.
Why are there two sets of accounting figures?
PRC securities rules require BeiGene to publish certain financial data under China Accounting Standards (PRC GAAP) in its STAR Market report. Those standards differ from U.S. GAAP in areas such as share-based compensation (accelerated versus straight-line expense recognition) and lease accounting (separate interest and depreciation presentation under PRC rules). The exhibit presents the U.S. GAAP versions of the required disclosures and summarizes the key differences.
What drove the improvement in gross margin?
Mix was the main driver. Ex-China revenue, which carries a gross margin of about 98%, grew far faster than China revenue, which carries about 68%. Ex-China cost of goods sold was only about $27 million on $1.36 billion of revenue. China gross margin improved slightly, from 67.1% to 68.0%, while ex-China margin eased slightly, from 98.3% to 98.0%.
Where is BeiGene investing its R&D budget?
Internal R&D accounted for about $1.13 billion of the $1.78 billion total in 2023. Zanubrutinib ($158 million) was the largest disclosed product program. The Bcl-2 program (BGB-11417) saw the fastest growth, more than doubling to $53 million. Spending on collaboration projects and ociperlimab declined, which suggests some reprioritization of the pipeline.
04—Continue